Alpha-MSH: natural skin-tanning, appetite, and anti-inflammation hormone
A hormone your body makes naturally that helps darken skin in the sun, signals the brain to curb appetite, and calms inflammation; it is not a drug but a substance everyone produces.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Alpha-melanocyte-stimulating hormone (α-MSH) is a 13-amino-acid peptide hormone that the human body produces naturally from a large precursor protein called pro-opiomelanocortin (POMC). It is not a synthetic drug or supplement — every person makes it continuously. α-MSH circulates and acts on several tissue types at once: in the skin it drives the tanning response, in the hypothalamus it is part of the brain circuit that tells you to stop eating, and in immune cells it damps down inflammation. The synthetic drugs discussed on wellness and aesthetic sites — Melanotan I (afamelanotide), Melanotan II, setmelanotide, and bremelanotide (PT-141) — are all laboratory-engineered versions of this one hormone, built to be more stable, more selective, or longer-lasting than the native molecule (Cai and colleagues, Current Protein & Peptide Science, 2016).
The stored sequence SYAMEHFRWGKPV is a 13-residue approximation. The biologically active hormone carries two modifications invisible in the raw string: an N-terminal acetyl group (Ac-) and a C-terminal amide (-NH₂), both of which protect the peptide from rapid degradation. The canonical human sequence has Ser at position 3; the stored sequence encodes Ala (A) at that position, reflecting a variant approximation in the platform database.
History
The discovery of α-MSH spans nearly a century. In 1916, Bennet Mills Allen and Philip E. Smith independently described a "skin-darkening" factor from pituitary extracts in amphibians — the functional discovery of melanocyte-stimulating hormone activity. Structural characterization followed in the 1950s, when Aaron Lerner's group and collaborating teams isolated α-MSH and β-MSH from pig and bovine pituitary pars intermedia extracts, and Klaus Hofmann's group at the University of Pittsburgh completed the total chemical synthesis of α-MSH — one of the earlier peptide-hormone total syntheses and proof that the 13-residue sequence carried full biological activity.
The relationship between α-MSH, ACTH, and β-endorphin was clarified in the 1970s and early 1980s when Shigetada Nakanishi and colleagues (1979) cloned the POMC cDNA and identified it as the single precursor from which all three are released by tissue-specific enzyme cleavage. The modern era of α-MSH pharmacology opened in 1992 when Roger Cone's group at the Vollum Institute cloned the first melanocortin receptors MC1R and MC2R (Mountjoy and colleagues, Science, 1992; PMID 1325670), followed rapidly by MC3R, MC4R, and MC5R. This receptor map explained why a single hormone could control pigmentation, appetite, adrenal function, and immune modulation through tissue-specific receptor expression (Switonski and colleagues, Journal of Applied Genetics, 2013).
In parallel, J. Michael Lipton and Anna Catania demonstrated in a series of papers from the late 1980s onward that α-MSH and its C-terminal tripeptide KPV (residues 11–13: Lys-Pro-Val) were potent anti-inflammatory agents — a property initially surprising for a "pigmentation hormone" but extensively replicated in skin, gut, ocular, and CNS inflammation models. The subsequent drug-development arc produced afamelanotide (Scenesse, FDA/EMA-approved 2019 for erythropoietic protoporphyria), setmelanotide (Imcivree, FDA-approved 2020 onward for rare monogenic obesity syndromes), and bremelanotide (Vyleesi, FDA-approved 2019 for hypoactive sexual desire disorder) — all engineered analogs of this endogenous hormone.
What it does
α-MSH acts through a family of five receptors (MC1R through MC5R), each concentrated in different tissues, which is why one hormone can have seemingly unrelated effects. Binding triggers elevation of cyclic AMP (cAMP) inside the target cell, leading to different downstream outputs depending on cell type.
In the skin, α-MSH released from keratinocytes after UV exposure binds MC1R on melanocytes and switches melanin synthesis toward the dark, protective form (eumelanin) over the lighter, sun-sensitive form (pheomelanin). It also enhances DNA repair after UV damage. This is the tanning response.
In the hypothalamus, α-MSH released from arcuate-nucleus POMC neurons acts on MC4R in the paraventricular nucleus to suppress appetite and increase energy expenditure. This is one half of the brain's weight-regulation circuit: leptin signals the body's fat mass to POMC neurons, which release α-MSH, which activates MC4R to reduce hunger. When this pathway is genetically broken — in POMC deficiency, PCSK1 mutations, or MC4R loss-of-function — the result is severe early-onset obesity, the class of conditions setmelanotide (/card/pep-10811) was approved to treat (Cai and colleagues, Current Protein & Peptide Science, 2016).
In immune cells, α-MSH and its C-terminal fragment KPV suppress production of pro-inflammatory signals and reduce fever. This anti-inflammatory activity operates through multiple routes including direct signaling on immune cells and intracellular suppression of the NF-κB pathway.
Native α-MSH itself is not used as a drug. Its plasma half-life is too short — degraded within minutes by circulating peptidases — making it impractical as an injectable therapeutic. All approved and investigational melanocortin drugs are protease-resistant analogs designed to overcome this limitation (Hruby and colleagues, Expert Opinion on Drug Discovery, 2011).
Evidence
- Human: α-MSH is a foundational physiological system with extensive clinical evidence through its analogs. Three FDA-approved drugs act through the α-MSH pathway: afamelanotide (Scenesse) for erythropoietic protoporphyria, setmelanotide (Imcivree) for POMC/PCSK1/LEPR deficiency and Bardet-Biedl syndrome and acquired hypothalamic obesity, and bremelanotide (Vyleesi) for premenopausal hypoactive sexual desire disorder — each representing clinical proof of concept for a different facet of α-MSH pharmacology. Native α-MSH is measured clinically in endocrinology (POMC deficiency, Cushing disease, craniopharyngioma follow-up) and dermatology research.
- Animal: Decades of rodent and primate work characterize POMC processing, hypothalamic circuitry, and melanocortin-receptor pharmacology. POMC-null, MC4R-null, and leptin-receptor-deficient knockout models are foundational obesity research tools. PC2-deficient mice — which cannot generate α-MSH from POMC — confirm PC2 as the required processing enzyme for pituitary and brain α-MSH production (PMID 12859669).
- In vitro: MC receptor pharmacology is extensively characterized in cell systems. The MC4R structural study by Yu and colleagues (Science, 2020) identified Ca²⁺ as a cofactor required for ligand binding — an unexpected finding with implications for understanding how the endogenous agonist and antagonist (AgRP) compete at the same receptor. Hruby and colleagues (Expert Opinion on Drug Discovery, 2011) review the receptor-binding pharmacology that underlies selective analog design.
Known effects
- Skin pigmentation (eumelanin synthesis) — MC1R-mediated; established physiology in humans and the pharmacological basis for afamelanotide's approval for EPP photoprotection
- Appetite suppression and energy balance — MC4R-mediated in hypothalamus; loss of this pathway is causal in monogenic obesity syndromes; the basis for setmelanotide's mechanism of action
- Anti-inflammatory and neuroimmunomodulatory activity — demonstrated in preclinical models across skin, gut, ocular, and CNS inflammation contexts; active at both the peptide level (via melanocortin receptors on immune cells) and through the C-terminal fragment KPV acting intracellularly on the NF-κB pathway
- UV-induced DNA repair enhancement — MC1R signaling in melanocytes also upregulates nucleotide excision repair of UV photoproducts; mechanistic basis characterized in human melanocyte culture (PMID 9523335)
- Sexual arousal — MC3R/MC4R-mediated centrally; the pharmacological basis for bremelanotide's approval; not demonstrated for native α-MSH specifically, but established for its synthetic analogs
- Exocrine secretion modulation — MC5R on sebaceous and lacrimal tissue; characterized preclinically; clinical relevance not established for native α-MSH
Safety signals
Pathological excess of α-MSH or POMC-derived melanocortins — as occurs in POMC-secreting tumors — is associated with hyperpigmentation, reflecting chronic MC1R activation. Pathological deficiency (monogenic POMC deficiency) causes severe early-onset obesity, red hair (loss of eumelanin bias), and adrenal insufficiency (because POMC is also the source of ACTH). These represent the extreme ends of the endogenous range rather than safety signals from exogenous administration.
For the approved analog drugs derived from α-MSH pharmacology, safety data are available from their respective clinical programs: nausea, flushing, and injection-site reactions for afamelanotide (Scenesse prescribing information); nausea and injection-site reactions for setmelanotide; transient increases in blood pressure and flushing for bremelanotide. Those signals belong to the individual analog cards, not to this entry on the endogenous hormone.
Native α-MSH is not a human therapeutic product and is not the subject of human safety studies as an administered compound.
Regulatory status
- Native α-MSH: Not a controlled substance. Not scheduled under the US Controlled Substances Act. Commercially available as a biochemical research reagent for cell-culture and preclinical animal work; not approved or intended for human administration.
- Approved analogs: Afamelanotide (Scenesse) — FDA-approved 2019, EMA-approved for EPP. Setmelanotide (Imcivree) — FDA-approved 2020 with subsequent label expansions, EMA-approved for rare monogenic obesity. Bremelanotide (Vyleesi) — FDA-approved 2019 for premenopausal HSDD. These are prescription-only specialty therapeutics; details on each are covered on their respective cards.
- WADA: Native α-MSH is an endogenous hormone and is not specifically listed on the WADA Prohibited List. Exogenous administration of any melanocortin agonist not approved for therapeutic use would fall under the S0 category (unapproved substances). Approved therapeutic analogs used with a Therapeutic Use Exemption may be permissible under their specific approval; athletes should consult applicable anti-doping authorities.
Myths and misconceptions
- "Alpha-MSH is a peptide I can buy and inject." Native α-MSH is not a human therapeutic. It is degraded within minutes in circulation, making it impractical as an injectable drug. Every melanocortin peptide sold or prescribed as a therapeutic — afamelanotide, setmelanotide, bremelanotide, Melanotan I and II — is a synthetic analog engineered specifically to overcome this limitation. Native α-MSH is available commercially only as a research reagent.
- "Melanotan II and alpha-MSH are the same thing." They are related but distinct. Melanotan II (/card/pep-00020) is a synthetic cyclic heptapeptide built to be a potent, broad-spectrum melanocortin agonist with extended duration. Native α-MSH is a linear 13-residue peptide with a short plasma half-life. Their receptor-selectivity profiles, pharmacokinetics, and clinical effect spectrums differ substantially, even though they share the same pharmacological family.
- "Alpha-MSH only affects skin color." α-MSH has at least three distinct well-characterized physiological roles: MC1R-mediated pigmentation, MC3R/MC4R-mediated appetite and energy-expenditure regulation in the hypothalamus (loss of which causes the monogenic obesities that setmelanotide treats), and broad anti-inflammatory/neuroimmunomodulatory activity. The pigmentation role is the one most people know; the metabolic and immune roles are at least as physiologically important (Cai and colleagues, Current Protein & Peptide Science, 2016).
- "Alpha-MSH and ACTH are the same hormone because they come from the same precursor." They share POMC origin but are distinct peptides. ACTH is a 39-residue unmodified peptide that binds MC2R (the adrenal receptor) and drives cortisol release from the adrenal cortex. α-MSH is a 13-residue acetylated/amidated peptide that binds MC1R, MC3R, MC4R, and MC5R but does not meaningfully activate MC2R and does not stimulate cortisol production — a distinction that is the mechanistic foundation of the MC2R specificity work by Fridmanis and colleagues (Frontiers in Endocrinology, 2017). The platform's stored target assignment of mc2r for this card reflects an error; the primary physiological targets of native α-MSH are MC1R, MC3R, and MC4R.
- "KPV is unrelated to alpha-MSH." KPV is the C-terminal tripeptide of α-MSH (residues 11–13: Lys-Pro-Val). It retains anti-inflammatory activity through intracellular NF-κB suppression rather than melanocortin-receptor binding and is a direct structural descendant of this endogenous hormone, not an independent molecule.
Mechanism
α-MSH is generated from POMC by sequential enzymatic cleavage: prohormone convertase PC1/3 and PC2 release a precursor peptide from POMC, which is then N-terminally acetylated (by opiomelanotropin-acetyltransferase) and C-terminally amidated (by peptidyl-glycine α-amidating monooxygenase, PAM) to yield the mature 13-residue Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂. The PC2 convertase is specifically required for α-MSH generation in the pituitary and brain (PMID 12859669). POMC is expressed in pituitary corticotrophs and pars intermedia melanotrophs, hypothalamic arcuate-nucleus and nucleus tractus solitarius POMC neurons, and peripherally in keratinocytes, melanocytes, and immune cells.
All five melanocortin receptors (MC1R–MC5R) are Gs-coupled GPCRs signaling through adenylyl cyclase, cAMP elevation, and downstream PKA/CREB activation. The pharmacologically critical His-Phe-Arg-Trp motif in the middle of the sequence (positions 6–9 in the 13-residue form, or 7–10 counting from ACTH numbering) is the core binding pharmacophore shared across the melanocortin peptide family and conserved across species (Dores and colleagues, Peptides, 1991).
At MC1R in melanocytes: cAMP elevation activates PKA, which phosphorylates CREB and drives upregulation of MITF — the master melanogenic transcription factor. MITF in turn induces expression of tyrosinase, TRP-1, and TRP-2, shifting melanin synthesis toward eumelanin. MC1R signaling also enhances nucleotide excision repair of UV photoproducts and modulates antioxidant defenses, providing photoprotection beyond simple pigmentation.
At MC4R in the hypothalamic paraventricular nucleus: α-MSH released from arcuate-nucleus POMC neurons — stimulated by leptin acting on LepRb receptors — activates MC4R to suppress appetite and increase sympathetic tone and energy expenditure. AgRP from an adjacent arcuate neuronal population acts as the endogenous inverse agonist at MC3R/MC4R, opposing the α-MSH satiety signal. The Ca²⁺ cofactor requirement for ligand binding at MC4R, identified by Yu and colleagues (Science, 2020), adds a further regulatory layer to receptor-agonist interaction.
At MC2R (the ACTH receptor): native α-MSH does not meaningfully activate MC2R — a receptor-specificity distinction that underlies why α-MSH does not drive adrenal cortisol secretion despite its POMC co-origin with ACTH. MC2R requires the full 1-24 sequence of ACTH for activation (Fridmanis and colleagues, Frontiers in Endocrinology, 2017).
Anti-inflammatory activity is mediated by multiple routes: direct MC1R, MC3R, and MC5R signaling on macrophages, neutrophils, and monocytes to suppress TNF-α, IL-1β, IL-6, and IL-8 production; and through the C-terminal tripeptide KPV, which translocates intracellularly and directly inhibits NF-κB p65 nuclear translocation independent of melanocortin-receptor binding.
Open questions
- The relative contribution of peripherally produced (keratinocyte, immune cell) versus centrally produced (hypothalamus, pituitary) α-MSH to systemic physiology is not fully resolved — whether local autocrine/paracrine α-MSH has meaningful endocrine effects beyond the tissue of origin remains an active research area.
- Tissue-specific POMC processing ratios — the exact proportions of α-MSH versus ACTH versus β-endorphin generated across pituitary pars distalis, pars intermedia, hypothalamic arcuate nucleus, and peripheral tissues, and how these ratios shift in obesity, inflammatory disease, and neurodegeneration — are incompletely characterized.
- The role of α-MSH in human melanoma biology is unsettled: evidence supports both a protective role (enhanced DNA repair, eumelanin-mediated photoprotection reducing mutation load) and a potentially adverse role (MC1R overexpression in metastatic melanoma possibly contributing to immune evasion).
- Whether near-native α-MSH could be formulated as a practical human therapeutic — using depot systems, peptidase-resistant backbone modifications, or fusion approaches — has not been explored clinically; the drug-development field has moved entirely to classical analog substitutions rather than formulation solutions.
- Biomarker utility of circulating α-MSH measurement in clinical endocrinology is technically feasible but reference ranges are unstandardized and the assay is not in routine clinical use.
Related peptides
- Melanotan I / afamelanotide — the FDA/EMA-approved MC1R agonist analog; protease-resistant 13-residue synthetic version developed for erythropoietic protoporphyria photoprotection
- Melanotan II — synthetic cyclic heptapeptide analog; broad-spectrum melanocortin agonist at MC1R/MC3R/MC4R/MC5R with extended duration compared with native α-MSH
- Setmelanotide (Imcivree) — MC4R-selective agonist approved for rare monogenic and acquired hypothalamic obesity; the clinical proof of concept for the leptin → POMC → α-MSH → MC4R satiety axis
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Is the MC2 receptor annotation for alpha-MSH a mistake, since alpha-MSH lacks the key amino acids that MC2R needs to respond?
Correcting this annotation matters for researchers and drug developers who study adrenal disorders or melanocortin biology. If alpha-MSH cannot activate MC2R, experiments or drug screens that assume otherwise would produce misleading results, wasting resources and potentially misdirecting development of cortisol-related therapies.
Could alpha-MSH or similar peptides reduce the harmful immune response in the brain that follows traumatic brain injury?
If alpha-MSH analogues can suppress brain inflammation after trauma, they could become the first class of drugs to limit the secondary brain damage that unfolds in the hours and days after a head injury. This could improve recovery outcomes for millions of people who experience TBI from accidents, falls, or combat injuries each year.
Could alpha-MSH suppress the immune cells attacking the joints in rheumatoid arthritis by activating the MC3 receptor?
If alpha-MSH can calm joint inflammation through MC3R, it could lead to a new class of biologic-free treatments for rheumatoid arthritis that are cheaper to produce and potentially safer for long-term use. This would matter especially for patients who cannot tolerate current immunosuppressive therapies because of infection risk.
Does the single amino acid difference at position 3 of this stored alpha-MSH sequence redirect it from the skin pigmentation receptor toward the brain's appetite-regulating receptor?
If Ala3 shifts activity from skin to brain receptors, this natural-looking variant could provide a cleaner tool for studying hunger regulation and metabolic disease without unwanted tanning side effects, potentially informing the design of purer anti-obesity drugs.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9032675623893738 | boltz-2 |
| ranking score | 0.8662466406822205 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10664,
sequence = {SYAMEHFRWGKPV},
target = {mc2r},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}